Clinical Trials Browser

Unknown × toripalimab × Thoracic × Clear all

NCT06208033 2024-01-17

SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)

Phase EARLY_PHASE1 Unknown

EGFR Positive Non-small Cell Lung Cancer

NCT05798533 2023-07-10

Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)

Phase 1 Unknown

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT05842018 2023-05-03

Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)

Phase 2 Unknown

Non Small Cell Lung Cancer Recurrent

NCT05652712 2022-12-15

A Real-World Study of Toripalimab in Chinese Patients With Lung Cancer(THUNDER Study)

Lung Neoplasms

NCT05162196 2022-05-02

The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer

Phase 2 Unknown

Small Cell Lung Carcinoma

NCT05055583 2021-09-24

Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04725448 2021-04-06

Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Thoracic Neoplasms

NCT04797702 2021-03-15

CT32

Phase 1/2 Unknown

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT04713761 2021-01-26

Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma

Phase 2 Unknown

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT04613804 2020-11-03

Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04316351 2020-07-23

Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance

Phase 2 Unknown

IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy

NCT03904719 2020-07-09

CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC)

Phase 2 Unknown

Small Cell Lung Carcinoma

NCT04193098 2020-07-07

Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLC

Phase 1 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04363255 2020-04-28

First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC

Phase 2 Unknown

Small Cell Lung Carcinoma

NCT02836834 2019-10-22

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid Tumors

Phase 1 Unknown

LymphoidThoracic

Lung Neoplasms, Lymphoma